Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.

被引:694
|
作者
Packard, CJ
O'Reilly, DSJ
Caslake, MJ
McMahon, AD
Ford, I
Cooney, J
Macphee, CH
Suckling, KE
Krishna, M
Wilkinson, FE
Rumley, A
Lowe, GDO
机构
[1] Glasgow Royal Infirm Univ NHS Trust, Glasgow Royal Infirm, Dept Pathol Biochem, Glasgow G31 2ER, Lanark, Scotland
[2] Glasgow Royal Infirm, Dept Med, Glasgow G31 2ER, Lanark, Scotland
[3] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[4] SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England
[5] diaDexus, Santa Clara, CA USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2000年 / 343卷 / 16期
关键词
D O I
10.1056/NEJM200010193431603
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Chronic inflammation is believed to increase the risk of coronary events by making atherosclerotic plaques in coronary vessels prone to rupture. We examined blood constituents potentially affected by inflammation as predictors of risk in men with hypercholesterolemia who were enrolled in the West of Scotland Coronary Prevention Study, a trial that evaluated the value of pravastatin in the prevention of coronary events. Methods: A total of 580 men who had had a coronary event (nonfatal myocardial infarction, death from coronary heart disease, or a revascularization procedure) were each matched for age and smoking status with 2 control subjects (total, 1160) from the same cohort who had not had a coronary event. Lipoprotein-associated phospholipase A(2), C-reactive protein, and fibrinogen levels and the white-cell count were measured at base line, along with other traditional risk factors. The association of these variables with the risk of coronary events was tested in regression models and by dividing the range of values according to quintiles. Results: Levels of C-reactive protein, the white-cell count, and fibrinogen levels were strong predictors of the risk of coronary events; the risk in the highest quintile of the study cohort for each variable was approximately twice that in the lowest quintile. However, the association of these variables with risk was markedly attenuated when age, systolic blood pressure, and lipoprotein levels were included in multivariate models. Levels of lipoprotein-associated phospholipase A(2) (platelet-activating factor acetylhydrolase), the expression of which is regulated by mediators of inflammation, had a strong, positive association with risk that was not confounded by other factors. It was associated with almost a doubling of the risk in the highest quintile as compared with the lowest quintile. Conclusions: Inflammatory markers are predictors of the risk of coronary events, but their predictive ability is attenuated by associations with other coronary risk factors. Elevated levels of lipoprotein-associated phospholipase A(2) appear to be a strong risk factor for coronary heart disease, a finding that has implications for atherogenesis and the assessment of risk. (N Engl J Med 2000;343:1148-55.) (C) 2000 Massachusetts Medical Society.
引用
收藏
页码:1148 / 1155
页数:8
相关论文
共 50 条
  • [1] Lipoprotein-associated Phospholipase A2 and Coronary Heart Disease
    Sofogianni, Areti
    Alkagiet, Stelina
    Tziomalos, Konstantinos
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (03) : 291 - 296
  • [2] Lipoprotein-associated phospholipase A2:: An independent predictor of coronary artery disease events in primary and secondary prevention
    Anderson, Jeffrey L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12A): : 23F - 33F
  • [3] Lipoprotein-associated Phospholipase A2 in Coronary Artery Disease
    Dimitroglou, Yannis
    Sakalidis, Athanasios
    Mavroudis, Andreas
    Kalantzis, Charalambos
    Valatsou, Angeliki
    Andrikou, Ioannis
    Christofi, Angela
    Mantzouranis, Emmanouil
    Kachrimanidis, Ioannis
    Bei, Evellina
    Lazarou, Emilia
    Tsioufis, Costas
    Tousoulis, Dimitris
    Lazaros, George
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2022, 22 (28) : 2344 - 2354
  • [4] Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target
    Packard, Chris J.
    CURRENT OPINION IN CARDIOLOGY, 2009, 24 (04) : 358 - 363
  • [5] Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: The Rancho Bernardo study
    Daniels, Lori B.
    Laughlin, Gall A.
    Sarno, Mark J.
    Bettencourt, Ricki
    Wolfert, Robert L.
    Barrett-Connor, Elizabeth
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (09) : 913 - 919
  • [6] Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke
    Muriel J Caslake
    Chris J Packard
    Nature Clinical Practice Cardiovascular Medicine, 2005, 2 : 529 - 535
  • [7] Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke
    Caslake, MJ
    Packard, CJ
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2005, 2 (10): : 529 - 535
  • [8] Lipoprotein-associated phospholipase A2 predicts heart failure hospitalization in coronary heart disease patients
    Ferreira, C.
    Baptista, R.
    Pego, J.
    Carmo, A.
    Ferreira, Ja
    Freitas, A.
    Milner, J.
    Martinho, S.
    Almeida, J. P.
    Campos, G.
    Rosa, J.
    Goncalves, L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 331 - 331
  • [9] Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis
    Li, Dongze
    Zhao, Lizhi
    Yu, Jing
    Zhang, Wei
    Du, Rongsheng
    Liu, Xin
    Liu, Ying
    Chen, You
    Zeng, Rui
    Cao, Yu
    Zeng, Zhi
    Zhao, Zhiwei
    Wu, Jiang
    CLINICA CHIMICA ACTA, 2017, 465 : 22 - 29
  • [10] Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans
    Yang, EH
    McConnell, JR
    Lennon, RJ
    Barsness, GW
    Pumper, G
    Hartman, SJ
    Rihal, CS
    Lerman, LO
    Lerman, A
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 344A - 344A